VegaShares Trillions ETF (TRIL)

Trillium Therapeutics Inc. (TRIL) is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for the treatment of cancer. The company's research and development efforts are focused on developing next-generation immunotherapies that target the tumor microenvironment and the immune system.

Trillium's lead drug candidate, TTI-621, is a novel fusion protein that targets the CD47 protein, a "don't eat me" signal expressed by tumor cells, which inhibits the body's immune system from attacking the cancer cells. The company is also developing other therapies that target the immune system, including TTI-622, a next-generation CD47-blocking agent, and TTI-2341, a novel STING agonist.

Additionally, the biopharmaceutical industry is subject to significant research and development costs, and the success of a company's products is often uncertain until clinical trials are completed.

They should also review the company's financial statements and other public disclosures to gain a better understanding of its financial performance and risks.